The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis - GBI Research Reports

The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis - GBI Research Reports
The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Published Dec 01, 2009
132 pages — Published Dec 01, 2009
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

SummaryGBI Research, the leading business intelligence provider, has released its latest research 'The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.' The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global monoclonal antibodies market. The report analyzes the markets for monoclonal antibodies in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, annual cost of therapy and market potential are forecast until 2015 for select segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes:- Annualized market data for the monoclonal antibodies market from 2000 to 2008, forecast forward to 2015- Analysis of the potential for the monoclonal antibodies market in select therapeutic areas. These include HER2 breast cancer, bone metastases, multiple sclerosis, Non Small Cell Lung cancer (NSCLC) and Rheumatoid Arthritis- Market characterization of the monoclonal antibodies market including market size, annual cost of therapy, sales volume and treatment usage patterns - Key drivers and barriers that have a significant impact on the market - Coverage of pipeline molecules in various phases of drug development - Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Abbott Laboratories, Johnson & Johnson, Merck & Co, Biogen Idec, AstraZeneca, Bristol -Myers Squibb, Elan Pharmaceuticals, Amgen Inc and Eli Lilly- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global monoclonal antibodies marketReasons to buyThe report will enhance your decision making capability. It will allow you to- Align product portfolio to the markets with high growth potential- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth - Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety- Develop key strategic initiatives by understanding key focus areas of leading companies - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

  
Source:
Document ID
GBIHC003MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents48
1.1 List of Tables82
1.2 List of Figures102
2 Global Monoclonal Antibodies Market: Introduction122
2.1 GBI Research Report Guidance131
3 Global Monoclonal Antibodies Market: Market Characterization1415
Introduction141
3.2 Revenue Forecasts for the Global MAbs Market Potential141
3.2.1 MAbs Treatment Potential142
3.2.2 Drug Prices161
3.2.3 Market Potential171
3.2.4 Market Potential Segmentation181
3.3 Revenue Forecasts of Global MAbs Market Actual Market191
3.3.1 MAbs Actual Treatment Population191
3.3.2 Actual Sales201
3.3.3 Actual Sales Segmentation212
3.4 Treatment Usage Patterns231
3.5 Global MAbs Trends241
3.5.1 Market Trends241
3.5.1.1 Big Pharmaceutical Companies Venturing into MAbs Market241
3.5.2 Technology Trends251
3.5.2.1 State-of-the-art R&D Technologies Expanding the Applications of MAbs to New Therapeutic Indications251
3.5.2.2 New Screening Technologies to Foster Monoclonal Antibody Development251
3.6 Product Trends251
3.6.1 Research and Development Focus Shifted Towards Humanized and Fully Humanized MAbs251
3.6.1.1 Horizontal Indication Expansion of Existing Mabs261
3.7 Global MAbs Market Drivers261
3.7.1 Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth261
3.7.2 Improved Side-effect Profiles and Tolerance of MAbs Therapy261
3.7.3 Lack of Effective Conventional Therapies Accelerates Utilization of MAbs261
3.7.4 Expanded Indications Opens up New Potential Patient Group271
3.7.5 Lack of Generics Augmented the Sales Growth of MAbs271
3.8 Global MAbs Market Restraints271
3.8.1 High Cost of MAbs Hampering the Growth of Treatment Population271
3.8.2 Adverse Effects Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy271
3.8.3 Industry Challenges Majority of MAbs Receive Approvals as Last Option Therapies281
3.9 Unmet Needs281
3.9.1 The High Cost of MAb Therapies is the Major Unmet Need and it is Also Responsible for Low Utilization by Patients281
3.9.2 MAbs Do Not Cure the Disease; They either Treat Signs and Symptoms or Decelerate Cell Proliferation281
4 Global MAbs Market Potential: Therapeutic Distribution2924
4.1 MAbs Market Potential in HER2 Breast Cancer (Adjuvant and Metastatic)291
4.1.1 Introduction291
4.1.1.1 Epidemiology291
4.1.1.2 Diagnosis301
4.1.1.3 Treatment301
4.1.2 Prescription Population311
4.1.3 Annual Cost of Therapy321
4.1.4 Market Potential331
4.2 MAbs Market Potential in Bone Metastases and Bone Loss Due to Cancer Therapy341
4.2.1 Introduction341
4.2.1.1 Epidemiology341
4.2.1.2 Diagnosis351
4.2.1.3 Treatment351
4.2.2 Prescription Population351
4.2.3 Annual Cost of Therapy361
4.2.4 Market Potential371
4.3 MAbs Market Potential in Relapsing-remitting Multiple Sclerosis (RRMS)381
4.3.1 Introduction381
4.3.1.1 Epidemiology381
4.3.1.2 Diagnosis391
4.3.1.3 Treatment401
4.3.2 Prescription Population401
4.3.3 Annual Cost of Therapy411
Market Potential421
4.4 MAbs Market Potential in Metastatic Non-Small Cell Lung Cancer (NSCLC)431
4.4.1 Introduction431
4.4.1.1 Epidemiology431
4.4.1.2 Diagnosis431
4.4.1.3 Treatment441
4.4.2 Prescription Population451
4.4.3 Annual Cost of Therapy451
4.4.4 Market Potential461
4.5 MAbs Market Potential in Rheumatoid Arthritis471
4.5.1 Introduction471
4.5.1.1 Epidemiology471
4.5.1.2 Diagnosis481
4.5.1.3 Treatment481
4.5.2 Prescription Population491
4.5.3 Annual Cost of Therapy501
4.5.4 Market Potential512
5 Global MAbs Market: Pipeline Analysis5333
Introduction531
5.2 MAbs Nomenclature531
5.3 Monoclonal Antibody Technology541
5.3.1.1 Hybridoma Technology541
5.3.1.2 FuCell Technology 551
Applications of MAbs551
5.4.1 Detection Assays 551
5.4.1.1 ELISA551
5.4.2 Purification Techniques 551
5.4.3 Gene Identification 551
5.4.4 Applied Chemistry551
5.4.5 Disease Therapy561
5.5 Therapeutic Applications in Oncology561
5.5.1 Introduction561
5.5.2 Marketed Therapies561
5.5.2.1 Rituxan561
5.5.2.2 Campath571
5.5.2.3 Herceptin581
5.5.2.4 Mylotarg581
5.5.2.5 Zevalin591
5.5.2.6 Bexxar591
5.5.2.7 Erbitux601
5.5.2.8 Avastin611
5.5.2.9 Vectibix611
5.5.3 Therapies in Late Stage Pipeline621
5.5.3.1 CP-751,871621
5.5.3.2 MK-0646631
5.5.3.3 SGN-35631
5.5.3.4 Trastuzumab-DM1 (T-DM1)631
5.5.3.5 CMC544641
5.5.3.6 Arzerra 641
5.5.3.7 Galiximab641
5.5.3.8 Lumiliximab651
5.5.3.9 Ipilimumab651
5.6 Therapeutic Applications in Autoimmune and Inflammatory Diseases661
Introduction661
5.6.2 Marketed Therapies661
5.6.2.1 Remicade661
5.6.2.2 Humira671
5.6.2.3 Raptiva681
5.6.2.4 Tysabri691
5.6.2.5 Cimzia701
5.6.2.6 Ilaris701
5.6.2.7 Simponi711
5.6.3 Therapies in Late Stage Pipeline711
5.6.3.1 Stelara711
5.6.3.2 Benlysta711
5.6.3.3 ABT-874721
5.6.3.4 Daclizumab731
5.6.3.5 Alemtuzumab731
5.7 Therapeutic Applications in Respiratory Diseases741
5.7.1 Introduction741
Marketed Therapies741
5.7.2.1 Xolair741
5.7.3 Therapies in Late Stage Pipeline751
5.7.3.1 MEDI-528751
5.8 Therapeutic Applications in Infectious Diseases751
5.8.1 Introduction751
5.8.2 Marketed Therapies761
5.8.2.1 Synagis761
5.8.3 Therapies in Pipeline761
5.8.3.1 ABthrax761
5.8.3.2 Numax771
Therapeutic Applications in Organ Transplantation771
5.9.1 Introduction771
5.9.2 Marketed Therapies781
5.9.2.1 Orthoclone OKT3781
5.9.2.2 Zenapax781
5.9.2.3 Simulect791
5.10 Therapeutic Applications in Cardiovascular Diseases791
5.10.1 Introduction791
5.10.2 Marketed Therapies801
5.10.2.1 Reopro801
5.10.3 Therapies in Pipeline811
5.10.3.1 TB-402811
5.11 New Indications811
5.11.1 Central Nervous System821
5.11.1.1 Solanezumab821
5.11.2 Diabetes831
5.11.2.1 Otelixizumab831
5.11.2.2 Teplizumab 831
5.12 Insights into Most Promising Drugs831
Denosumab831
5.12.1.1 Introduction831
5.12.1.2 Mechanism of Action841
5.12.1.3 Clinical Trial Management841
5.12.1.4 Market Potential851
6 Global MAbs Market: M&A Landscape868
6.1 Overview861
6.1.1 Emergent BioSolutions acquires Avanir Pharmaceuticals861
6.1.2 MacroGenics acquires Raven Biotechnologies861
6.1.3 Thermo Fisher acquires Affinity BioReagents871
6.2 R&D Licensing Agreements 871
6.2.1 Deals by Phase871
6.2.2 Deals by Geography871
6.2.3 Deals by Licensing Type881
6.2.4 Deals by Value ($)881
6.2.5 Preclinical891
6.2.5.1 AVP 21D9:891
6.2.5.2 DX-2240891
6.2.5.3 Anti LIGHT Monoclonal Antibody891
6.2.5.4 Anti-L1 891
6.2.6 Phase I901
6.2.6.1 AMG 557901
6.2.6.2 Elotuzumab901
6.2.7 Phase II911
6.2.7.1 R7159911
6.2.7.2 GA101911
6.2.8 Phase III921
6.2.8.1 Campath921
6.2.9 Approved921
6.2.9.1 Vectibix922
7 Global MAbs Market: Competitive Landscape9434
7.1 Evolving competitive landscape941
7.1.1 Major players941
7.1.2 Key MAbs in the Market951
7.2 Company Benchmarking Analysis962
7.3 Roche/Genentech982
7.3.1 Key Monoclonal Antibody Drugs 1001
7.3.1.1 Rituxan1001
7.3.1.2 Avastin1011
7.3.1.3 Herceptin1011
7.3.1.4 Lucentis1021
7.3.1.5 Xolair1021
7.3.1.6 Raptiva1021
7.3.1.7 Actemra1021
7.3.2 Key Indications of Interest1021
7.3.3 Pipeline Analysis1031
7.4 Abbott 1041
7.4.1 Key MAbs1051
7.4.1.1 Humira1051
7.4.2 Key Indications of Interests1061
7.4.3 Pipeline Analysis1061
Johnson &Johnson1061
7.5.1 Key MAbs1071
7.5.1.1 Stelara1071
7.5.1.2 Remicade1071
7.5.2 Key Indications of Interest1081
7.5.3 Pipeline Analysis1081
7.6 Biogen Idec.1091
7.6.1 Key MAbs1101
7.6.1.1 Lumiliximab1101
7.6.1.2 Rituxan (rituximab)1101
7.6.1.3 Tysabri (natalizumab)1111
7.6.2 Key Indications of Interest1111
7.6.3 Pipeline Analysis1111
7.7 Merck/Schering Plough1121
7.7.1 Key MAbs1131
7.7.1.1 Remicade1131
7.7.1.2 Simponi1131
7.7.2 Key Indications of Interest1131
7.7.3 Pipeline Analysis1141
7.8 AstraZeneca1151
7.8.1 Key MAbs1151
7.8.1.1 Synagis 1151
7.8.2 Key Indications of Interest1161
7.8.3 Pipeline Analysis1161
7.9 Bristol-Myers Squibb1171
7.9.1 Key MAbs1181
7.9.1.1 Erbitux1181
7.9.2 Key Indications of Interest1181
Elan 1191
7.10.1 Key MAbs1201
7.10.1.1 Tysabri 1201
7.10.2 Key Indications of Interest1201
7.10.3 Pipeline Analysis1211
7.11 Eli Lilly1221
7.11.1 Key Monoclonal Antibody Drugs1231
7.11.1.1 Reo Pro1231

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis" Dec 01, 2009. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Monoclonal-Antibodies-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis-2115-4>
  
APA:
GBI Research Reports. (2009). The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis Dec 01, 2009. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Monoclonal-Antibodies-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis-2115-4>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.